| __timestamp | Iovance Biotherapeutics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 5078000000 |
| Thursday, January 1, 2015 | 12390000 | 4717000000 |
| Friday, January 1, 2016 | 25602000 | 5096000000 |
| Sunday, January 1, 2017 | 21262000 | 4986000000 |
| Monday, January 1, 2018 | 28430000 | 4214000000 |
| Tuesday, January 1, 2019 | 40849000 | 3806000000 |
| Wednesday, January 1, 2020 | 60210000 | 3671000000 |
| Friday, January 1, 2021 | 83664000 | 3528000000 |
| Saturday, January 1, 2022 | 104097000 | 3445000000 |
| Sunday, January 1, 2023 | 106916000 | 3498000000 |
| Monday, January 1, 2024 | 3702000000 |
Data in motion
In the competitive landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Teva Pharmaceutical Industries Limited and Iovance Biotherapeutics, Inc. from 2014 to 2023.
Teva, a global leader in generic medicines, consistently reported SG&A expenses in the billions, peaking at approximately $5 billion in 2016. However, a downward trend is evident, with a 32% reduction by 2023. In contrast, Iovance, a pioneering biotech firm, saw its SG&A expenses grow over tenfold, from around $9 million in 2014 to over $106 million in 2023. This reflects Iovance's aggressive expansion and investment in innovation.
The contrasting trajectories of these companies highlight the diverse strategies within the pharmaceutical sector, where established giants and emerging innovators navigate financial landscapes differently.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Bio-Techne Corporation
Teva Pharmaceutical Industries Limited vs Viking Therapeutics, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Teva Pharmaceutical Industries Limited and Protagonist Therapeutics, Inc.
Selling, General, and Administrative Costs: Teva Pharmaceutical Industries Limited vs Mesoblast Limited
Teva Pharmaceutical Industries Limited vs Celldex Therapeutics, Inc.: SG&A Expense Trends
Neurocrine Biosciences, Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Iovance Biotherapeutics, Inc.
CymaBay Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Arrowhead Pharmaceuticals, Inc. or Iovance Biotherapeutics, Inc.
Mesoblast Limited or Iovance Biotherapeutics, Inc.: Who Manages SG&A Costs Better?